Telehealth Market

Investor Series: Opportunities in the Telehealth Market - Focus on [A] Need for Telehealth Solutions / Services, [B] Landscape of Key Innovators, [C] Analysis of Product Offerings and Affiliated Value Propositions, [D] Insights from Historical Funding Activity, [E] Startup Health Indexing and Company Valuation Analysis, [F] Financial Analysis of Key Public Ventures, [G] Market Forecast and Opportunity Analysis, [H] Insights from Publicly Disclosed Investor Exits and [I] Key Acquisition Targets

  • Lowest Price Guaranteed From USD 1,899

  • Published
    January 2022

  • Pages
    121

  • View Count
    2394

  • Buy Now

Example Insights

Investor-Series-Opportunities-in-the-Telehealth-Context-thumb Investor-Series-Opportunities-in-the-Telehealth-Experts-thumb Investor-Series-Opportunities-in-the-Telehealth-Service-Providers-thumb Investor-Series-Opportunities-in-the-Telehealth-Services-Market-thumb Investor-Series-Opportunities-in-the-Telehealth-Start-ups-thumb Investor-Series-Opportunities-in-the-Telehealth-begun-thumb Investor-Series-Opportunities-in-the-Telehealth-Indexing-thumb Investor-Series-Opportunities-in-the-Telehealth-Value-Proposition-thumb
Investor-Series-Opportunities-in-the-Telehealth-competitive-edge-thumb Investor-Series-Opportunities-in-the-Telehealth-impetus-thumb Investor-Series-Opportunities-in-the-Telehealth-publicly-listed-thumb Investor-Series-Opportunities-in-the-Telehealth-investors-thumb Investor-Series-Opportunities-in-the-Telehealth-overall-thumb Investor-Series-Opportunities-in-the-Telehealth-Related-Details-thumb Investor-Series-Opportunities-in-the-Telehealth-Teladoc-Health-thumb Investor-Series-Opportunities-in-the-Telehealth-Financial Ratios-thumb
Investor-Series-Opportunities-in-the-Telehealth-Stock-Performance-thumb Investor-Series-Opportunities-in-the-Telehealth-Analysis-Tools-thumb Investor-Series-Opportunities-in-the-Telehealth-Financial-Analysis-thumb Investor-Series-Opportunities-in-the-Telehealth-Risk-Assessment-thumb Investor-Series-Opportunities-in-the-Telehealth-Opportunity-Analysis-thumb Investor-Series-Opportunities-in-the-Telehealth-pandemic-thumb Investor-Series-Opportunities-in-the-Telehealth-opportunity-thumb Investor-Series-Opportunities-in-the-Telehealth-Acquisition-Targets-thumb

Overview

Telehealth refers to the remote delivery of healthcare services, such as medical consults, examination / interpretation of medical reports, critical health parameter monitoring, medical information sharing (between physicians and their patients) and patient education, using modern telecommunications solutions. In other words, it offers a convenient and cost-effective way for individuals with health problems to seek medical attention from the comfort of their respective homes. Currently, a wide variety of virtual conferencing tools and intuitive software are available for the aforementioned purposes. In fact, during the COVID-19 pandemic, due to the enforcement of mandatory social distancing practices, a lot of routine and emergency medical consultations were reported to have been conducted in the virtual environment. In 2020, it was estimated that 76% of hospitals in the US were using diverse telehealth technologies to connect doctors to patients.  Although the demand for and use of telehealth technologies witnessed a notable surge (experts believe that the use of such solutions increased by around 40% compared to the pre-COVID era) during the recent pandemic, the idea of remote delivery of medical advice / information is believed to have been conceived much earlier. It is, therefore, safe to infer that the pandemic served to provide a much-needed impetus to drive the adoption of remote medical services. Moreover, even as social distancing mandates are being revoked across the world, the expanded access to quality healthcare offered by telemedicine is anticipated to continue to be used at a less unprecedented but evident scale. 

The recent years have witnessed a surge in investment activity in companies involved in the development of telehealth solutions. This was primarily fueled by the demand for remote healthcare services, which led to a marked increase in the adoption of various telemedicine, health tracking and medical information sharing products. According to one of our recent studies, many companies are also engaged in providing tailored solutions, along with remote access to medical care facilities to patients. In addition, around 90% of the healthcare organizations are believed to have already invested or have revealed strong intentions to invest in remote patient monitoring systems. In the wake of the recent increase in demand, we believe that the market presents lucrative investment opportunities for investors on the lookout for both short- and long-term gains.

Scope of the Report

The “Investor Series: Opportunities in the Telehealth Market” report provides detailed information on the telehealth industry, covering the core and peripheral products and affiliated services. It offers a technical and financial perspective on how the opportunity in this domain is likely to evolve, in terms of promising business ventures, over the coming decade. The information in this report has been presented across multiple deliverables, featuring interactive MS Excel sheets and an MS PowerPoint deck, which summarizes the key takeaways from the project, and insights drawn from the curated data. The report features the following details:

  • A qualitative perspective on the current need for telehealth solutions and services, highlighting some of the key applications of such offerings and featuring information on the various companies that are engaged in this domain (along with details of some exemplary ventures that have either succeeded or failed in this market). 
  • A detailed analysis of telehealth focused companies that were established on or after 2005, featuring inputs on observed trends related to basic input parameters, such as year of establishment, headquarters, company size, and type of venture. 
  • A quantitative perspective on the relative health (based on basic company details, product details, financing activity, and estimated revenues and profits) of the different innovator companies that have been described in detail in this report. This analysis is based on a proprietary scoring criterion, informed via secondary research. 
  • An assessment of the various products and affiliated services, offered by the companies mentioned above, featuring analysis based on number and type of product, and an informed perspective on the value of the aforementioned offerings based on multiple relevant aspects, namely applicability and adoption trends, treatment-related value, value to patients, value to patients and healthcare professionals, and others.  
  • A company competitiveness analysis, offering a quantitative basis for comparing the diverse telehealth solutions captured in this report, based on the insights generated from the abovementioned analyses.
  • A detailed analysis of the funding and investment activity that has taken place in this domain, since 2011. It also includes financing category-wise trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the key innovator companies discussed in the report. Further, it features a list of the leading investors in telehealth, based on their participation in financing activity in this domain. 
  • A proprietary analysis defining a basis for estimating the relative valuation of the private companies among the key innovators discussed in this report. Estimates presented in the report were based on information gathered via secondary research, for a sample set of companies. Key inferences drawn from the sample set were extrapolated using the appropriate mathematical models to generate valuation estimates for all companies in the dataset.
  • An elaborate review of the overall telehealth market from a financial perspective, including detailed fundamental (insights from the balance sheet, and key financial ratios) and technical analyses (insights from historical and recent stock price variations, and analysis using popular stock performance indicators) of financial data of the publicly listed companies within the key innovators dataset. 
  • A business risk analysis, based on some of the major categories of risk that are usually discussed in the industry – namely operations-related risks, overall business-related risks, financial risks, product / technology associated risks, and social, economic, environmental and political risks. 
  • Case studies of instances where investors have exited various telehealth-related ventures, offering insights on returns on investment made (based on availability of data). Leveraging the abovementioned details, the report offers an informed opinion on the future outlook for investors in the telehealth market. 
  • A key acquisition targets analysis, based on the insights generated during the course of this study, highlighting some of the promising early-to-mid stage business ventures around which there is likely to be interest (in terms of acquisition potential).

One of the key objectives of the report was to evaluate the current opportunity and the future potential of the site management organizations market over the coming decades. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2021-2035. The opportunity has been segregated on the basis of [A] key market segments (namely telemedicine (which further includes interactive patient care, store & forward telemedicine and remote patient monitoring offerings), patient portals and tele-education) and [B] geography (North America, Europe, Asia Pacific and the rest of the world). To account for future uncertainties in the market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

Contents

DELIVERABLE OUTLINES

Excel Deliverables

Sheet I includes details on the key innovator companies captured in the report along with a summary dashboard, featuring interactive graphical representations of key insights generated from the company health indexing, value proposition analysis and company competitiveness analysis. This sheet also includes details of our proprietary key acquisition targets analysis. 

Sheet II features a summary dashboard, including interactive graphical representations of some of the key insights generated related to the capital investments made in telehealth (since 2011) and our proprietary company valuation analysis (focused on the key innovator companies that have not yet gone public). 

Sheet III is a summary of insights generated from a detailed fundamental and technical financial analysis, of publicly listed ventures in the key innovators dataset. It also offers a pictorial perspective on some of the major areas of risk associated with telehealth. It is worth mentioning that for each company, there is a separate MS Excel sheet, which provides information on key financial parameters and competitive insights based on historical and prevalent trends. 

Sheet IV is a summary MS Excel dashboard, offering detailed graphical representations of the contemporary and future opportunity associated with telehealth. It also includes a collection of publicly available information on the investments made by select investors in companies that are now publicly listed. Based on the aforementioned information, the sheet offers a proprietary perspective on likely returns on investment received by the mentioned investors. 

PowerPoint Deliverable: Key Section Outlines

Section I describes the current need for telehealth solutions and services, highlighting some of their key application areas. It includes information on the various companies that are engaged in this domain, along with details of some exemplary ventures that have either succeeded or failed in this market. It also features inputs from representatives from key stakeholder companies in this domain (as stated in publicly available articles and interview transcripts). The section concludes with information on the different conferences that have been conducted in this domain in the recent past. 

The section also provides a [A] detailed analysis of telehealth focused innovator companies that were established on or after 2005. The section features basic company related details, such as year of establishment, headquarters, company size, and type of venture. It also includes [B] information on the various products and affiliated services, including analysis based on number and type of product, which are offered by the aforementioned companies. Based on the abovementioned insights, it offers a [C] quantitative perspective on the relative health (based on basic company details, product details, financing activity, and estimated revenues and profits) of the different innovator companies. In addition, it offers an informed perspective on the key [D] value proposition of the same companies based on multiple relevant aspects, namely applicability and adoption trends, treatment-related value, value to patients, value to patients and healthcare professionals, and others. Finally, based on the aforementioned inputs, the section features a detailed [E] company competitiveness analysis, offering a quantitative basis for comparing the diverse telehealth solutions captured in this report. It is worth mentioning that the analysis described in this section is based on proprietary scoring criteria, which was informed via secondary research.

Section II offers insights from a detailed [A] analysis of the funding and investment activity that has taken place in this domain, since 2011. It also includes financing category-wise trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the key innovator companies discussed in the report. Further, it features a proprietary basis for [B] estimating the relative valuation of the private companies among the key innovators discussed in this report. It is worth mentioning that the aforementioned estimations were based on information gathered via secondary research, for a sample set of companies. Key inferences drawn from the sample set were extrapolated using the appropriate mathematical models to generate valuation estimates for all companies in the dataset.

Section III is modelled in the likeness of an equity research report. It features a review of the overall telehealth market from a financial perspective and includes detailed fundamental (insights from the balance sheet, and key financial ratios) and technical analyses (insights from historical and recent stock price variations, and analysis using popular stock performance indicators) of financial data of six of the publicly listed companies within the key innovators dataset. 

Section IV includes a business risk analysis, offering insights encompassing several known categories of risk; these include operations-related risks, business-related risks, product / technology risks, financial / asset-related risks, and other risks.

Section V features is an insightful market forecast analysis, highlighting the estimated current and future sizes of overall telehealth market till the year 2035. The opportunity has been segregated on the basis of [A] key market segments (namely telemedicine (which further includes interactive patient care, store & forward telemedicine and remote patient monitoring offerings), patient portals and tele-education) and [B] geography (North America, Europe, Asia Pacific and the rest of the world). It also includes case studies of instances where investors have exited various telehealth-related ventures, offering insights on returns on investment made (based on availability of data). Based on the abovementioned details, it provided an informed opinion on the future outlook for investors in the telehealth market. 

Section VI offers insights from a proprietary analysis that leverages inputs from the startup health indexing and value proposition analysis (described in section I), to offer qualitative recommendations on companies that are likely to be perceived as key acquisition targets.

Table Of Contents

Excel Deliverable

1. Key Innovators Dataset
1.1. Summary Dashboard
1.2. Key Innovators Dataset
1.3. Telehealth Products Dataset
1.4. Company Health Indexing
1.5. Value Proposition Analysis
1.6. Company Competitiveness Analysis
1.7. Key Acquisition Targets

2. Analysis of Funding & Company Valuation
2.1. Summary Dashboard
2.2. Capital Investments in Telehealth
2.3. Company Valuation Analysis

3. Fundamental & Technical Financial Analysis
3.1. Summary Dashboard
3.2. Business Risk Analysis

4. Opportunity Analysis & Mapping Key Investor Exits
4.1. Summary Dashboard
4.2. Market Forecast & Opportunity Analysis
4.3. Analysis of Key Investor Exits

PowerPoint Deliverable

1. Context
2. Project Approach
3. Project Objectives
4. Executive Summary

Section I: Need for Telehealth Solutions & Key Innovators Landscape

5. Contemporary Telehealth Market
5.1. Need for Telehealth Solutions / Services
5.2. Industry Expert Perspective
5.3. Key Initiatives in Telehealth (Case Studies)
5.3.1. Exemplary Business Successes
5.3.2. Exemplary Business Failures 
5.4. Analysis of Recent Conferences

6. Key Innovators Market Landscape
6.1. Overview
6.2. Key Innovators in Telehealth
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Type / Stage of Venture
6.2.4. Analysis by Geographical Location
6.3. Concluding Remarks

7. Key Products Landscape
7.1. Overview
7.2. Telehealth Products and Affiliated Services
7.2.1. Analysis by Type of Product
7.2.2. Analysis by
7.3. Concluding Remarks

8. Company Health Indexing and Value Proposition Analysis
8.1. Overview
8.2. Company Health Indexing
8.3. Value Proposition Analysis
8.4. Company Competitiveness Analysis
8.5. Concluding Remarks

Section II Analysis of Investments & Company Valuation

9. Funding and Investments Analysis
9.1. Overview of Funding Activity, 2011-2021
9.1.1. Analysis by Year of Funding
9.1.2. Analysis by Type of Funding
9.1.3. Analysis by Type of Funding and Amount Invested
9.1.4. Funding and Investments Summary

10. Company Valuation Analysis
10.1. Overview
10.2. Valuation Analysis
10.2.1. Approach 1: Based on Estimated Valuation
10.2.2. Approach 2: Based on Estimated Value and Revenues
10.2.3. Approach 3: Based on Stage of Financing
10.3. Conclusion

Section III Fundamental & Technical Financial Analysis

11. Financial Analysis of Public Ventures
11.1. Overview
11.2. 23andMe
11.2.1. Fundamental Analysis of Company Financials
11.2.1.1. Insights from Balance Sheet
11.2.1.2. Analysis of Financial Ratios
11.2.2. Technical Analysis of Stock Price
11.2.2.1. Historical Trends
11.2.2.2. Recent Trends

11.3. Accolade
11.3.1. Fundamental Analysis of Company Financials
11.3.1.1. Insights from Balance Sheet
11.3.1.2. Analysis of Financial Ratios
11.3.2. Technical Analysis of Stock Price
11.3.2.1. Historical Trends
11.3.2.2. Recent Trends

11.4. Amwell
11.4.1. Fundamental Analysis of Company Financials
11.4.1.1. Insights from Balance Sheet
11.4.1.2 Analysis of Financial Ratios
11.4.2. Technical Analysis of Stock Price
11.4.2.1. Historical Trends
11.4.2.2. Recent Trends

11.5. Dialogue
11.5.1. Fundamental Analysis of Company Financials
11.5.1.1. Insights from Balance Sheet
11.5.1.2. Analysis of Financial Ratios
11.5.2. Technical Analysis of Stock Price
11.5.2.1. Historical Trends
11.5.2.2.Recent Trends

11.6. Talkspace
11.6.1. Fundamental Analysis of Company Financials
11.6.1.1. Insights from Balance Sheet
11.6.1.2. Analysis of Financial Ratios
11.6.2. Technical Analysis of Stock Price
11.6.2.1. Historical Trends
11.6.2.2. Recent Trends

11.7. Teladoc Health
11.7.1. Fundamental Analysis of Company Financials
11.7.1.1. Insights from Balance Sheet
11.7.1.2. Analysis of Financial Ratios
11.7.2. Technical Analysis of Stock Price
11.7.2.1. Historical Trends
11.7.2.2. Recent Trends

Section IV Business Risk Analysis

12.  Risk Analysis of Public Companies
12.1. Overview
12.2. Business Risk Analysis
12.2.1. Operations-related Risks
12.2.2. Business-related Risks
12.2.3. Product / Technology Risks
12.2.4. Financial / Asset-related Risks
12.2.5. Other Risks
12.3. Concluding Remarks

Section V Opportunity Analysis & Mapping Key Investor Exits

13. Market Forecast and Opportunity Analysis
13.1. Overview and Methodology
13.2. Overall Telehealth Market Size, 2021-2035
13.2.1. Analysis by Key Market Segments
13.2.2. Analysis by Geography
13.2.3. Concluding Remarks

14. Investor Exits & Estimated Returns on Investment
14.1. Outlook for Investors
14.2. Publicly Disclosed Investor Exits
14.2.1. Estimated Returns on Investment
14.3. Concluding Remarks

15. Key Acquisition Targets
15.1. Overview
15.2. Analysis of Key Acquisition Targets
15.3. Concluding Remarks

16. Appendices I: Tabulated Data

17. Appendices II: List of Companies & Organizations

List Of Companies

The following companies and organizations have been mentioned in the report.

  1. 406 Ventures
  2. 14W
  3. 20/20 HealthCare Partners
  4. 415 Ventures
  5. 7wire Ventures
  6. 8VC
  7. A.Capital
  8. Aaron Patzer
  9. AB Kinnevik
  10. Abu Dhabi Investment Office
  11. Accel
  12. Accelerator
  13. Access Industries
  14. Acme Capital
  15. ACRA
  16. Acrew Capital
  17. Acrew Capital’s Scout Fund
  18. Activant Capital
  19. Adam Balon
  20. Adamed
  21. Adaptive Healthcare Fund
  22. Add Health Media 
  23. Affinity Capital Management
  24. Air Angels
  25. AirAngels
  26. AirTree Ventures
  27. Ajit Gunewardene
  28. ALES Global Japan
  29. Allianz X
  30. Ally Bridge Group
  31. Ally Bridge Group (ABG) 
  32. Alma Mundi Fund
  33. Alma Mundi Ventures
  34. Alphabet’s investment arm
  35. Altimeter Capital
  36. Alumni Ventures Group
  37. Amazon
  38. AME Cloud Ventures
  39. American Investment Holdings
  40. Amgen
  41. Amgen Ventures
  42. Amgen Ventures
  43. Amit Bhatia 
  44. and Eliana Murillo
  45. and Fosun Pharma
  46. and New Capital Partners
  47. and others.
  48. and Skip Battle
  49. and Starbucks
  50. Andreessen Horowitz
  51. Anne Wojcicki
  52. Anshumani Ruddra
  53. Anthem Health
  54. Antonio Gracias
  55. Ardea Capital Partners
  56. Arizona Founders Fund
  57. Arthur Ventures
  58. Artis Ventures
  59. Ascension Ventures
  60. Asia Africa Investment & Consulting
  61. Asia Partners
  62. Aspect Ventures
  63. Atento Capital
  64. Athenahealth
  65. Athensmed
  66. Atlantic Labs
  67. Atomico
  68. Autonomous Ventures
  69. Avalon Ventures
  70. AWE Funds
  71. AXA Venture Partners (AVP)
  72. Axilor Ventures
  73. Baidu Ventures
  74. Baillie Gifford
  75. Bain Capital Ventures
  76. Bain Capital Ventures. Uprising
  77. Baring Vostok
  78. Barry Sternlicht
  79. Bascom Ventures
  80. Base10 Partners
  81. Battery Ventures
  82. Bayer
  83. BDC Capital
  84. Bessemer Venture Partners
  85. Bill Ackman
  86. Black Pearls VC
  87. Blackbird
  88. Blackbird Ventures
  89. Blue Cross Blue Shield of Massachusetts
  90. Blue Ivy Ventures
  91. Blue Venture Fund
  92. Blueprint Health
  93. BlueRun Ventures
  94. BOND
  95. Bootstrap Incubation
  96. Boston Millennia Partners
  97. BoxGroup
  98. BPEA
  99. Bracket Capital
  100. Breyer Capital
  101. Bridges Israel
  102. BrightEdge
  103. Brown Angel Group
  104. Burst Capital
  105. Caisse de dépôt et placement du Québec (CDPQ)
  106. California Health Care Foundation Innovation Fund
  107. Cambia Health Solutions
  108. Canaan Partners
  109. Canada Pension Plan Investment Board
  110. Canvas
  111. Canvas Ventures
  112. Capital Union Investments
  113. Cardinal Partners
  114. Casdin Capital
  115. CDPQ
  116. Centene
  117. Centre for Innovation Incubation and Entrepreneurship (CIIE)
  118. Cherif Habib
  119. Chris Burch
  120. CICC
  121. Cigna Ventures
  122. City Light Capital
  123. Claes Dinkelspiel
  124. Clark Valberg
  125. Clearvision Equity
  126. CMI Ventures
  127. Collaborative Fund
  128. Colle Capital Partners
  129. Colorado Impact Fund
  130. Comcast Ventures
  131. Company Ventures
  132. Compound Ventures
  133. Connect the Grey Investment Management
  134. Corisol Holding
  135. Corisol Holdings
  136. Correlation Ventures
  137. Cowen Private Investments
  138. Cox Enterprises
  139. CQRS Limited
  140. Creadev
  141. Creandum
  142. Creathor Ventures
  143. Crosscut Ventures
  144. CRV
  145. CSIRO’s VC fund
  146. CU Healthcare Innovation Fund
  147. CU Healthcare Innovation Fund 
  148. Cumberland VC
  149. D1 Capital Partners
  150. Daniel Gulati
  151. Dara Khosrowshahi
  152. David Ellison
  153. David H. Petraeus
  154. Debiopharm Innovation Fund
  155. Dedalus Group
  156. Deena Shakir
  157. Deerfield Management Company
  158. Define Ventures
  159. Demis Hassabis
  160. DFJ
  161. Digital Future
  162. Digital Health Ventures
  163. Dioko Health Ventures
  164. Dioko Health Ventures
  165. Discount Tech
  166. Dr. Jeremy Lim
  167. Dr. Mark Friedman
  168. Dr. Rushika Fernandopoulle
  169. Dragoneer Investment Group
  170. Dreamers Fund
  171. Drive Capital
  172. dRx Capital
  173. DRX Capital
  174. DST Global
  175. Dubai Angel Investors
  176. Dundee Venture Capital
  177. e.ventures
  178. Early Light Ventures
  179. EASME - EU Executive Agency for SMEs
  180. Echo Health
  181. Echo Health Ventures
  182. ECMC
  183. EDBI
  184. Eight Roads Ventures
  185. Emily Melton
  186. Emmett Partners
  187. Eniac Ventures
  188. Equity Venture Partners
  189. ERGO Fund
  190. Eric Schmidt’s Innovation Endeavors
  191. ES Investor
  192. Esther Dyson
  193. Euclidean Capital
  194. European Commission 
  195. Exponent
  196. F Cubed
  197. Faber Ventures
  198. Fairview Health Services
  199. Female Founders Fund
  200. Fidelity Management & Research
  201. Fidelity Management & Research Company
  202. FinSight Ventures
  203. FinX Capital
  204. First Ascent Ventures
  205. First Trust Capital Partners
  206. FirstMark Capital
  207. FirstTime.
  208. FJ Labs
  209. FLAG Capital Management
  210. Flashpoint Venture Capital
  211. Flint Capital
  212. Florian Jansen
  213. Fosun Pharma
  214. Founders Fund
  215. F-Prime Capital
  216. F-Prime Capital
  217. F-Prime Capital Partners
  218. Francisco Partners
  219. Freestyle Capital
  220. Frist Cressey Ventures
  221. Future Perfect Ventures
  222. Gaingels
  223. GAN
  224. GAN Ventures
  225. Gates Foundation
  226. GE Ventures
  227. General Atlantic
  228. General Catalyst
  229. Geoff Price
  230. George Ruan
  231. GGV Capital
  232. GlaxoSmithKline
  233. Global Voyager Fund 
  234. Glynn Capital Management
  235. Goldman Sachs Investment Partners
  236. Goldman Sachs Merchant Banking Division
  237. Goldman Sachs’ merchant banking
  238. Goodwater Capital
  239. Google Cloud
  240. Google Ventures
  241. Google’s VC
  242. Gradient Ventures
  243. Grand Central Tech Ventures
  244. Great Oaks VC
  245. Great Oaks Venture Capital
  246. Green Innovations
  247. Greenspring Associates
  248. Groupe Arnault
  249. GSMA Ecosystem Accelerator
  250. GSR Ventures
  251. Guidewell
  252. GuideWell Mutual Holding Corporation
  253. GV
  254. GV 
  255. Hacking Health Accelerator.
  256. Hambrecht Ducera Growth Ventures
  257. Harmony Partners
  258. Harri Tilev
  259. Hashtag One
  260. Hawke Ventures
  261. HBM Healthcare Investment
  262. HBM Healthcare Investments
  263. Headwater VC
  264. Health Catalyst Capital
  265. Health Velocity Capital
  266. HealthInvest Equity Partners
  267. HEALTHY VENTURES
  268. Henley Business Angels
  269. Heritage Medical Systems
  270. Heritage Provider Network
  271. Highline
  272. Highmark Ventures
  273. Hikma Ventures
  274. HIMAngel
  275. HLM Venture Partners
  276. HLM Ventures
  277. Holtzbrinck Ventures
  278. Horizon 2020 SME support program.
  279. Horizon BlueCross BlueShield of New Jersey
  280. Howard Jenkins
  281. Hoxton Ventures
  282. HPE Growth
  283. Huajin Fund
  284. Humana
  285. Hustle Fund
  286. Hyde Park Venture Partners
  287. Hyperplane Capital
  288. Icon Ventures
  289. IDFC Alternatives
  290. Idinvest Partners
  291. iGlobe Partners
  292. IHH Healthcare
  293. Illumina
  294. Illumina Ventures
  295. Impact Investments
  296. including Optum Ventures
  297. Index Ventures
  298. Indie.vc
  299. Inflection Capital
  300. Ingleside Investors
  301. Inkef Capital
  302. INKEF Capital
  303. InnoVen Capital
  304. InnoVision Capital
  305. Insight Partners
  306. Intel Capital
  307. International Finance Corporation (IFC)
  308. InvAscent
  309. Inventus Capital
  310. IRA Capital
  311. Israeli Innovation Authority
  312. Ithmar Capital Partners
  313. J.P. Morgan
  314. Jackson Square Ventures
  315. JAFCO Asia Fund
  316. Jafco Ventures
  317. Jamie McCourt
  318. Jason Calacanis
  319. Jawed Karim
  320. Jeff Weiner
  321. Jefferson Health System
  322. Jeremy Andrus
  323. Jeremy Yap
  324. Jerry Yang
  325. Jim Foreman
  326. John Simon
  327. Jon Wright
  328. Jonathan Bush
  329. June Fund
  330. Justin Kan
  331. Kae Capital
  332. Kae Capital 
  333. Kaiser Permanente Ventures 
  334. Kaiser Permanente Ventures and Illumina Ventures
  335. Kamet Capital
  336. Kamet Capital Partners
  337. Ken Goulet
  338. Ken Griffin
  339. Kenneth Griffin
  340. Kevin Hill
  341. Kevin Scott
  342. Khosla Ventures
  343. Khosla Ventures 
  344. Khosla Ventures.
  345. Kickstart Seed Fund
  346. Kim Hammonds
  347. Kima Ventures
  348. Kinnevik
  349. Kleiner Perkins
  350. Kleiner Perkins Caufield & Byers
  351. Kleiner Perkins Caufield and Byers
  352. Kustaa Piha
  353. L Catterton 
  354. LabCorp
  355. Lachy Groom
  356. Lanka Orix Leasing Company
  357. Lead Edge Capital
  358. Len Blavatnik’s global investment group
  359. Leonard Lynch
  360. Lerer Hippeau
  361. Lerer Hippeau Ventures
  362. Lerer Ventures
  363. LetsVenture
  364. LifeSci Ventures
  365. Lightspeed Venture Partners
  366. Lightspeed Venture Partnersl
  367. Lightspeed Ventures
  368. LionBird
  369. Lionel Richie
  370. Liquid 2 Ventures
  371. LLC
  372. Lori Goler
  373. LPs Bill
  374. LRVHealth
  375. Lux Capital
  376. Lux Capital 
  377. M25
  378. M25 Group
  379. MadhanKumar Madathupalayam
  380. MAF Mauritius
  381. Main Sequence Ventures
  382. Manatt Venture Fund
  383. March Capital
  384. Mark Leslie
  385. Martin Ventures 
  386. Matrix Partners
  387. Matt Mullenweg
  388. Maven Ventures
  389. Maverick Capital Ventures
  390. Maverick Ventures
  391. Mayfield Fund
  392. Maynard Webb
  393. Medical Angels investment group
  394. Mellon and QuestMark Partners
  395. MemorialCare Innovation Fund (MCIF)
  396. Merck Global Health Innovation Fund
  397. Mercury Fund
  398. Metamorphic Ventures
  399. Metsola Ventures
  400. Michael Stoppelman
  401. Microsoft
  402. Microsoft Ventures
  403. Mike Silagadze
  404. Mike Wortsman
  405. Mikhail Sokolov 
  406. Mikhail Tsyferov
  407. Milliways Ventures
  408. Mindy Kaling
  409. MK Capital
  410. Mohr Davidow Ventures
  411. Montage Ventures
  412. Morado Ventures
  413. Morningside Ventures
  414. MPM Capital
  415. MPOF Mauritius
  416. Mubadala Ventures
  417. Mustafa Suleyman 
  418. Nat Turner
  419. Natalie Portman
  420. Nathan and Sonia Baschez
  421. Nathan Kirsh
  422. Natie Kirsh
  423. National Bank of Canada
  424. National Center for Research and Development
  425. National Institutes of Health
  426. New Capital Partners and Trident Capital
  427. New Enterprise Associates
  428. New Enterprise Association
  429. new investors Blue Cloud Ventures
  430. New York Angels
  431. NewFlight
  432. NewView Capital
  433. NEXT Canada
  434. Next Ventures
  435. Next Wave Impact Fund
  436. NextView Ventures
  437. NGP Capital
  438. NGP Capital.
  439. Nikhil Krishnan
  440. Nokia Growth
  441. Norwest Venture Partners
  442. Norwest Venture Partners
  443. Norwest Venture Partners
  444. Notation Capital
  445. Novartis
  446. Novartis Venture Fund
  447. Novo Holdings
  448. Novotech Health Holdings
  449. Oak HC/FT
  450. Obvious Ventures
  451. Obvious Ventures 
  452. Olive Tree Ventures
  453. Omidyar Network
  454. Omphalos Venture Partners
  455. Omphalos Ventures
  456. Ontario Centres of Excellence
  457. Ontario Teachers’ Pension Plan
  458. operational VC
  459. Optum Ventures. Centene Corporation
  460. Orbimed
  461. OrbiMed Israel Partners
  462. ORIX Growth Capital
  463. ORIX Healthcare Capital
  464. Orpah Winfrey
  465. Owl Ventures
  466. Oxeon Investments
  467. Palm Drive Capital
  468. Parkview Investment Advisors
  469. Patrick J. Kennedy.
  470. Patrick Spain
  471. Paul Buchheit
  472. Paul Jaobs
  473. Pavilion Capital
  474. Pelion Venture Partners
  475. Per Båtelson
  476. Perceptive Advisors
  477. Peterson Ventures
  478. Philips
  479. Phoenix Ventures
  480. physician-led MEDA Angels
  481. PinPoint Ventures
  482. PKO VC
  483. Portag3 Ventures
  484. PPD
  485. PPD
  486. PPD 
  487. Precursor Ventures
  488. Prime Capital
  489. Princeville Global
  490. Pritzker Capital
  491. Pritzker Group Venture Capital
  492. Prodeko Ventures
  493. Programa
  494. Project A
  495. Project A Ventures
  496. Project A.
  497. Qualcomm Ventures
  498. Questa Capital
  499. Questa Capital Management
  500. Qumra Capital
  501. Qura
  502. Qure
  503. Rand Capital
  504. Randor
  505. Reaktor Ventures
  506. Real Ventures
  507. Rebright Partners
  508. Redmile Group
  509. Redwood Global Healthcare Fund
  510. Reese Witherspoon
  511. Revolution Growth
  512. Richard Park
  513. Richard Reed
  514. Ridgeview Asset Management
  515. Right Side Capital Management
  516. RLJ Equity Partners
  517. Roche Venture Fund
  518. Rockies Venture Club
  519. Rockies Venture Fund
  520. Rohini Pandhi
  521. Rohit M.A.
  522. Romulus Capital
  523. Rucker Park Capital
  524. Rushan Venture Capital 
  525. Rushika Fernandopulle 
  526. Rustic Canyon Partners
  527. Safeguard Scientifics
  528. Sami Inkinen
  529. Samsung Catalyst Fund
  530. Sand Hill Angels
  531. Sanofi
  532. Sanofi Ventures
  533. Sanofi-Genzyme BioVentures
  534. Sapphire Ventures
  535. Saudi Arabia’s Public Investment Fund
  536. Saudi’s Athaal Group
  537. SBK Tech Ventures
  538. Scale AI
  539. SEI Ventures
  540. Sequoia
  541. Sequoia Capital
  542. Sequoia Capital India
  543. Seraph Group
  544. Sergey Brin
  545. Service Provider Capital
  546. Seyen Capital 
  547. Shakopee
  548. Shasta Ventures
  549. Shasta Ventures 
  550. Shea Ventures
  551. Sherpa Ventures
  552. Sierra Ventures
  553. SignalFire
  554. Signia Venture Partners
  555. Silicon Valley Bank
  556. Silver Lake Waterman
  557. Silverton Partners
  558. Sir Richard Branson
  559. Slauson & Co.
  560. Slow Ventures
  561. Soft Bank
  562. Softbank
  563. SoftBank
  564. Sogou
  565. Soma Capital
  566. Sound Ventures
  567. Spark Capital
  568. SpeedUp Venture Capital Group
  569. Spring Lake Equity Partners
  570. Spring Mountain Capital
  571. Spring Mountain Capital 
  572. Sputnik ATX
  573. SputnikATX Ventures
  574. Square Peg
  575. Stage 2 Capital
  576. Stanford Health Care
  577. Starting Line
  578. Startup Health
  579. Sterling’s capital
  580. Steve Shulman
  581. Steven Cohen
  582. Storm Ventures
  583. Streamlined Ventures
  584. Streamlined Ventures.
  585. Streamlined Ventures. 
  586. Stride Ventures
  587. Structure Capital
  588. Summation Health Ventures
  589. Sun Life
  590. Susan Lyne
  591. SV Angel
  592. Takeda
  593. Taru Kapoor
  594. Tata Group
  595. TDJ Pitango Ventures
  596. TEAMFund LP
  597. Tech Council Venture
  598. Techstars
  599. Teladoc Health
  600. Tenaya Capital
  601. Tencent
  602. Tesi
  603. Teuza
  604. The American Cancer Society
  605. the Colorado Impact Fund
  606. The Council
  607. The Daube Family office
  608. The Family
  609. The Jump Fund
  610. The Living Fund.
  611. The Mayfield Fund
  612. The Valley Fund
  613. The Cooperative Research Centre Project
  614. TheTime
  615. Thomas Lehrman
  616. Three Fields Capital
  617. Three Leaf Ventures
  618. Tiger Global and Qumra Capital
  619. TKS I
  620. Tobias Lütke
  621. Todd Cozzens
  622. Tom Meredith
  623. Tony Fadell's Future Shape 
  624. Town Hall Ventures
  625. Transformation Capital
  626. Trans-Pacific Technology Fund
  627. Trident Capital
  628. TrueSight Ventures
  629. Trustbridge
  630. TT Capital Partners
  631. Tull Investment Group
  632. Tusk Venture Partners
  633. Tusk Venture Partners 
  634. TVC Capital
  635. Two Sigma Ventures
  636. Two Sigma Ventures 
  637. TYLT Labs
  638. UC San Francisco
  639. Union Square Ventures
  640. Uniqa Ventures
  641. Unitus Ventures
  642. University Growth Fund
  643. Unpopular Ventures
  644. Unseen Capital
  645. Urban Capital Network
  646. Vega Ventures
  647. Velocity
  648. Venrock
  649. Venture Catalysts
  650. Venture Founders
  651. Vertical Venture Partner
  652. Vesalius Biocapital
  653. Vesalius Biocapital and Faber
  654. Vesalius Biocapital III
  655. Vida Ventures
  656. Vir Kashyap
  657. VMG Partners
  658. VNV Global
  659. Vostok New Ventures 
  660. W23
  661. Walgreens
  662. Walgreens Boots Alliance
  663. Wallenberg Foundation
  664. Walter Capital National Bank of Canada
  665. Walter Financial
  666. Walter Ventures
  667. Wanxiang America Corporation
  668. Waterline Ventures
  669. Waypoint Capital Partners
  670. Webb Investment Network
  671. Wefunder
  672. WELL Health Technologies
  673. Westcap
  674. Western Technology Investment
  675. WestTech Ventures 
  676. White Star Capital
  677. Whittier Ventures
  678. Wild Ventures
  679. William Tunstall-Pedoe
  680. Wittington Ventures
  681. Workday Ventures
  682. World Innovation Lab Venrock
  683. WTI and other unnamed individual investors
  684. WuXi Healthcare Ventures
  685. Xfund
  686. Y Combinator
  687. Yahoo founder Jerry Yang’s AME Cloud Ventures
  688. Yandex
  689. Yuri Milner
  690. Zac Weinberg
  691. Zaffre Investments
  692. Ziegler LinkAge Fund

PRICING DETAILS

USD 1,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experienceAccept

Copyright © 2023 Roots Analysis. All Rights Reserved.